Use of rifamycins in HIV-infected patients.
Preboth
M
M
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000037:antagonists & inhibitors*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects*; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000037:antagonists & inhibitors*; D006801:Humans; D017828:Rifabutin / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D012294:Rifamycins / Q000008:administration & dosage / Q000494:pharmacology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D017320:HIV Protease Inhibitors; D012294:Rifamycins; D017828:Rifabutin; D003577:Cytochrome P-450 Enzyme System; D012293:Rifampin